NasdaqGS:CFMS

Stock Analysis Report

Executive Summary

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • Conformis has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Conformis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.6%

NasdaqGS:CFMS

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

63.6%

NasdaqGS:CFMS

9.7%

US Medical Equipment

1.9%

US Market

CFMS outperformed the Medical Equipment industry which returned 9.6% over the past year.

CFMS outperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

CFMSIndustryMarket
7 Day2.6%1.5%0.8%
30 Day-4.3%0.7%3.4%
90 Day-53.4%2.4%2.1%
1 Year63.6%63.6%10.6%9.7%4.2%1.9%
3 Year-78.7%-78.7%70.2%65.0%46.7%37.2%
5 Yearn/a136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Conformis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Conformis undervalued based on future cash flows and its price relative to the stock market?

4.98x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Conformis to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Conformis to establish if it is available at substantial discount.


Price Based on Earnings

Conformis is loss making, we can't compare its value to the US Medical Equipment industry average.

Conformis is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Conformis, we can't assess if its growth is good value.


Price Based on Value of Assets

Conformis is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Conformis expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

16.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Conformis's revenue is expected to grow by 4% yearly, however this is not considered high growth (20% yearly).

Conformis is not considered high growth as it is expected to be loss making for the next 1-3 years.

Conformis's revenue growth is positive but not above the United States of America market average.

Unable to compare Conformis's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Conformis's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Conformis will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Conformis performed over the past 5 years?

5.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Conformis does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Conformis's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Conformis's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Conformis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Conformis has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Conformis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Conformis's financial position?


Financial Position Analysis

Conformis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Conformis's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Conformis's level of debt (70.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (11.5% vs 70.8% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Conformis has less than a year of cash runway based on current free cash flow.

Conformis has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -31.7% each year.


Next Steps

Dividend

What is Conformis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Conformis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Conformis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Conformis has not reported any payouts.

Unable to verify if Conformis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Conformis has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Conformis's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Mark Augusti (53yo)

2.8yrs

Tenure

US$1,231,541

Compensation

Mr. Mark A. Augusti has been Chief Executive Officer and President at ConforMIS, Inc. since November 14, 2016. Mr. Augusti's 27-year business career has been marked with executive management responsibility ...


CEO Compensation Analysis

Mark's remuneration is higher than average for companies of similar size in United States of America.

Mark's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.5yrs

Average Tenure

54yo

Average Age

The tenure for the Conformis management team is about average.


Board Age and Tenure

10.6yrs

Average Tenure

55yo

Average Age

The average tenure for the Conformis board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

Conformis individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$4,11709 Aug 19
Paul Weiner
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares2,480
Max PriceUS$1.66
SellUS$12,43209 Aug 19
Mark Augusti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares7,489
Max PriceUS$1.66
SellUS$1,842,99522 Jul 19
Archon Capital Management LLC
EntityCompany
Shares613,594
Max PriceUS$3.21
SellUS$2,659,16411 Jul 19
Archon Capital Management LLC
EntityCompany
Shares702,295
Max PriceUS$3.83
SellUS$44,67103 Jul 19
Paul Weiner
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares10,764
Max PriceUS$4.15
SellUS$99,01903 Jul 19
Mark Augusti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares23,860
Max PriceUS$4.15
SellUS$11,66017 May 19
Paul Weiner
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares3,303
Max PriceUS$3.53
SellUS$24,02917 May 19
Mark Augusti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares6,807
Max PriceUS$3.53
SellUS$34,32608 May 19
Paul Weiner
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares12,612
Max PriceUS$2.72
SellUS$15,76908 May 19
Patricia Davis
EntityIndividual
Shares5,794
Max PriceUS$2.72
SellUS$69,33608 May 19
Mark Augusti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares25,477
Max PriceUS$2.72
SellUS$7,89507 Mar 19
Patricia Davis
EntityIndividual
Shares6,266
Max PriceUS$1.26
SellUS$1,69807 Feb 19
Paul Weiner
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares2,294
Max PriceUS$0.74
BuyUS$229,60004 Jan 19
Archon Capital Management LLC
EntityCompany
Shares560,000
Max PriceUS$0.41
SellUS$1,85407 Dec 18
Mark Augusti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares2,706
Max PriceUS$0.69
SellUS$78317 Oct 18
Paul Weiner
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares833
Max PriceUS$0.94

Ownership Breakdown


Management Team

  • Paul Weiner (55yo)

    CFO & Treasurer

    • Tenure: 5.4yrs
    • Compensation: US$649.03k
  • Mark Augusti (53yo)

    CEO, President & Director

    • Tenure: 2.8yrs
    • Compensation: US$1.23m
  • Ed Kilgallen

    Vice President of Operations

    • Tenure: 2.1yrs
  • Daniel Steines (50yo)

    Consultant

    • Tenure: 0.9yrs
    • Compensation: US$888.98k
  • John Slamin (65yo)

    Senior Vice President of Product Engineering

    • Tenure: 11.9yrs
  • Manny Nyakako

    Senior Vice President of Quality & Regulatory Affairs

    • Tenure: 2.5yrs
  • J. Allredge

    Chief Legal Officer & Corporate Secretary

    • Tenure: 0.2yrs

Board Members

  • Ken Fallon (80yo)

    Chairman of the Board

    • Tenure: 4.6yrs
    • Compensation: US$178.45k
  • Brad Langdale (55yo)

    Director

    • Tenure: 11.3yrs
    • Compensation: US$144.45k
  • Mark Augusti (53yo)

    CEO, President & Director

    • Tenure: 2.8yrs
    • Compensation: US$1.23m
  • Brian McKeon

    Member of the Scientific Advisory Board

    • Tenure: 10.6yrs
  • Thomas Thornhill

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Minas

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Wolfgang Fitz

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Richard Scott

    Member of Scientific Advisory Board

    • Tenure: 10.8yrs
  • Amar Ranawat

    Member of the Scientific Advisory Board

    • Tenure: 10.6yrs
  • Anil Ranawat

    Member of the Scientific Advisory Board

    • Tenure: 10.6yrs

Company Information

Conformis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Conformis, Inc.
  • Ticker: CFMS
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$135.984m
  • Shares outstanding: 68.68m
  • Website: https://www.conformis.com

Number of Employees


Location

  • Conformis, Inc.
  • 600 Technology Park Drive
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CFMSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2015
308DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2015

Biography

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaini ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:26
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.